Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 106

    1.

    What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?

    Campbell GR, Loret EP.

    Retrovirology. 2009 May 25;6:50. Review.

    PMID:
    19467159
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection.

    Huigen MC, Kamp W, Nottet HS.

    Eur J Clin Invest. 2004 Jan;34(1):57-66. Review.

    PMID:
    14984439
    [PubMed - indexed for MEDLINE]
    3.

    Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.

    Gupta S, Mitra D.

    Indian J Biochem Biophys. 2007 Oct;44(5):269-75. Review.

    PMID:
    18341200
    [PubMed - indexed for MEDLINE]
    4.

    Recent advances in the development of HIV-1 Tat-based vaccines.

    Caputo A, Gavioli R, Ensoli B.

    Curr HIV Res. 2004 Oct;2(4):357-76. Review.

    PMID:
    15544457
    [PubMed - indexed for MEDLINE]
    5.

    Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.

    Ramakrishna L, Anand KK, Mohankumar KM, Ranga U.

    J Virol. 2004 Sep;78(17):9174-89.

    PMID:
    15308713
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.

    Moreau E, Belliard G, Partidos CD, Pradezinsky F, Le Buanec H, Muller S, Desgranges C.

    J Gen Virol. 2004 Oct;85(Pt 10):2893-901.

    PMID:
    15448351
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription.

    Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, Franchini G.

    J Biol Chem. 2003 Apr 4;278(14):12310-8. Epub 2002 Dec 24.

    PMID:
    12501250
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.

    Cafaro A, Caputo A, Maggiorella MT, Baroncelli S, Fracasso C, Pace M, Borsetti A, Sernicola L, Negri DR, Ten Haaft P, Betti M, Michelini Z, Macchia I, Fanales-Belasio E, Belli R, Corrias F, Buttò S, Verani P, Titti F, Ensoli B.

    J Med Primatol. 2000 Aug;29(3-4):193-208.

    PMID:
    11085582
    [PubMed - indexed for MEDLINE]
    9.

    Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.

    Kolson DL, Collman R, Hrin R, Balliet JW, Laughlin M, McGann KA, Debouck C, Gonzalez-Scarano F.

    J Gen Virol. 1994 Aug;75 ( Pt 8):1927-34.

    PMID:
    8046394
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    UV and X-ray structural studies of a 101-residue long Tat protein from a HIV-1 primary isolate and of its mutated, detoxified, vaccine candidate.

    Foucault M, Mayol K, Receveur-Bréchot V, Bussat MC, Klinguer-Hamour C, Verrier B, Beck A, Haser R, Gouet P, Guillon C.

    Proteins. 2010 May 1;78(6):1441-56.

    PMID:
    20034112
    [PubMed - indexed for MEDLINE]
    11.

    Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.

    Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B.

    Rev Recent Clin Trials. 2009 Sep;4(3):195-204. Review.

    PMID:
    20028332
    [PubMed - indexed for MEDLINE]
    12.

    Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine.

    Blazevic V, Männik A, Malm M, Sikut R, Valtavaara M, Toots U, Ustav M, Krohn K.

    AIDS Res Hum Retroviruses. 2006 Jul;22(7):667-77.

    PMID:
    16831091
    [PubMed - indexed for MEDLINE]
    13.

    Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.

    Ensoli B, Cafaro A.

    J Biol Regul Homeost Agents. 2000 Jan-Mar;14(1):22-6.

    PMID:
    10763887
    [PubMed - indexed for MEDLINE]
    14.

    The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.

    Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E.

    AIDS. 2008 Oct 18;22(16):2207-9.

    PMID:
    18832884
    [PubMed - indexed for MEDLINE]
    15.

    HIV-1 Tat-based vaccines: from basic science to clinical trials.

    Fanales-Belasio E, Cafaro A, Cara A, Negri DR, Fiorelli V, Butto S, Moretti S, Maggiorella MT, Baroncelli S, Michelini Z, Tripiciano A, Sernicola L, Scoglio A, Borsetti A, Ridolfi B, Bona R, Ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Vardas E, Magnani M, Laguardia E, Caputo A, Titti F, Ensoli B.

    DNA Cell Biol. 2002 Sep;21(9):599-610. Review.

    PMID:
    12396602
    [PubMed - indexed for MEDLINE]
    16.

    Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.

    Re MC, Gibellini D, Vitone F, La Placa M.

    New Microbiol. 2001 Apr;24(2):197-205. Review.

    PMID:
    11346305
    [PubMed - indexed for MEDLINE]
    17.

    Tits and bits of HIV Tat protein.

    Johri MK, Mishra R, Chhatbar C, Unni SK, Singh SK.

    Expert Opin Biol Ther. 2011 Mar;11(3):269-83. Epub 2011 Jan 5. Review.

    PMID:
    21204735
    [PubMed - indexed for MEDLINE]
    18.

    Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

    Gringeri A, Santagostino E, Muça-Perja M, Mannucci PM, Zagury JF, Bizzini B, Lachgar A, Carcagno M, Rappaport J, Criscuolo M, Blattner W, Burny A, Gallo RC, Zagury D.

    J Hum Virol. 1998 May-Jun;1(4):293-8.

    PMID:
    10195254
    [PubMed - indexed for MEDLINE]
    19.

    Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins.

    Rolland M, Jensen MA, Nickle DC, Yan J, Learn GH, Heath L, Weiner D, Mullins JI.

    J Virol. 2007 Aug;81(16):8507-14. Epub 2007 May 30.

    PMID:
    17537854
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection.

    Devadas K, Boykins RA, Hewlett IK, Wood OL, Clouse KA, Yamada KM, Dhawan S.

    Peptides. 2007 Mar;28(3):496-504. Epub 2006 Dec 22.

    PMID:
    17188401
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk